Nuclear Imaging in Renal Cell Carcinoma: Current Evidence and Clinical Applications

Al-Khanaty, A; Qin, S; Delgado, C; Hennes, D; Dinneen, E; Chen, D; Au, L; Eapen, RS; Bolton, D; Murphy, DG; Lawrentschuk, N; Jack, G; Moon, D; Hofman, MS; Perera, ML

Author(s): Al-Khanaty, A; Qin, S; Delgado, C; Hennes, D; Dinneen, E; Chen, D; Au, L; Eapen, RS; Bolton, D; Murphy, DG; Lawrentschuk, N; Jack, G; Moon, D; Hofman, MS; Perera, ML;
Details: Publication Year 2026-01-07,Volume 18,Issue #2,Page 195
Journal Title: Cancers
Publication Type: Review
Abstract: Introduction: Radiotracer-based nuclear imaging, including positron emission tomography (PET) and single-photon emission computed tomography (SPECT), can complement conventional cross-sectional imaging in renal cell carcinoma (RCC) by providing biological characterisation of tumour metabolism, angiogenesis, hypoxia, and the tumour microenvironment. While computed tomography (CT) and magnetic resonance imaging (MRI) remain the diagnostic standard, accumulating evidence suggests that selected nuclear imaging techniques may offer incremental value in specific clinical scenarios. Methods: A narrative literature review was performed using PubMed, Embase, and Web of Science to identify preclinical, retrospective, and prospective studies evaluating PET and SPECT radiotracers in localised and metastatic RCC. Priority was given to meta-analyses, multicentre prospective trials, and studies with histopathological correlation. Results: [(18)F]fluorodeoxyglucose (FDG) PET/CT demonstrates limited sensitivity for primary renal tumours (pooled sensitivity of approximately 60%) but performs substantially better in metastatic and recurrent disease (pooled sensitivity and specificity of approximately 85-90%), where uptake correlates with tumour grade, progression-free survival, and overall survival. [(99m)Tc]sestamibi SPECT/CT differentiates oncocytoma and hybrid oncocytic/chromophobe tumours from malignant RCC with pooled sensitivity and specificity of around 85-90%, supporting its role in evaluating indeterminate renal masses rather than staging. Prostate-specific membrane antigen (PSMA) PET/CT shows high detection rates in clear-cell RCC, particularly in metastatic disease, with reported sensitivities of approximately 85-90% and management changes in up to 40-50% of selected cohorts. Carbonic anhydrase IX (CAIX)-targeted PET/CT enables the biologically specific visualisation of clear-cell RCC, achieving sensitivities and specificities in the range of 85-90% in prospective phase II and III trials for primary tumour characterisation. Fibroblast activation protein inhibitor (FAPI) PET/CT demonstrates high tumour-to-background uptake in early RCC studies, but evidence remains preliminary, with small cohorts and recognised non-specific uptake in benign inflammatory and fibrotic conditions. Conclusions: Radiotracer-based nuclear imaging provides complementary, biology-driven insights in RCC that extend beyond anatomical assessment. While most modalities remain adjunctive or investigational and are not recommended for routine use, selective application in carefully chosen clinical scenarios may enhance tumour characterisation, prognostication, and personalised treatment planning.
Publisher: MDPI
Keywords: Pet/ct; PSMA-targeted imaging; [18f]fdg; carbonic anhydrase IX; clear-cell renal cell carcinoma; fibroblast activation protein inhibitor; nuclear imaging; renal cell carcinoma
Department(s): Surgical Oncology; Medical Oncology; Cancer Imaging
Publisher's Version: https://doi.org/10.3390/cancers18020195
Open Access at Publisher's Site: https://doi.org/10.3390/cancers18020195
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2026-02-03 06:11:40

Last Modified: 2026-02-03 06:11:50